ERBB2 and cancer: On the other hand, trastuzumab decreased tumor VEGF expression through the PI3K/Akt pathway in HER-2/neu-positive cancer cells[11,37-39], and could also increase anti-angiogenic factor and inhibit additional pro-angiogenic factors such as transforming growth factor-α, angiopoietin-1, plasminogen-activator inhibitor-1, and interleukin(IL)-8 [11,37].